Anti-GPCR1 ADC: SKM104-MA L2 as a Highly Differentiated Candidate Ready for IND Studies

  • Exploring GPCR1 target multi-tumour expression, low healthy tissue expression, internalization, and lysosomal trafficking 
  • Detailing SKM104 antibody high affinity to tumour cells, crossreactivity in cynos and low or no binding to normal cells 
  • Demonstrating preclinical safety with no off-target side effects; HNST not reached at the highest dose of 145 mg/kg in rats 
  • Showcasing the Skymab reversible platform with enhanced efficacy in resistant tumours, stability, and pharmacokinetics